Tysabri gets European backing at EMEA

Tysabri has taken one more step back to the global market, winning a recommendation from the European Medicines Agency that the multiple sclerosis drug be returned for restricted use. The EMEA advised the EU that Tysabri should be marketed for relapsing-remitting MS patients, delaying disability progression and reducing the rate of relapses. An FDA committee recommended that Tysabri be marketed as a first-line therapy for all MS sufferers. Tysabri was pulled early last year after it was linked to three cases of a rare brain disease. Elan's shares surged four percent on the news.

- here's the Marketwatch article for more information

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.